Purpose: Previous research findings on the association between serum total bilirubin (TB) and cardiovascular events varied with different study populations. Our objective was to clarify the association between serum TB at admission and long-term adverse outcomes in patients with acute coronary syndrome (ACS) and stable angina (SA) undergoing percutaneous coronary intervention (PCI). Patients and methods: This prospective cohort study included 2,502 patients who underwent PCI. Information on the study population was obtained from the Dryad Digital Repository. The patients were divided into two groups: high (>0.60 mg/dL) and low TB groups (≤0.60 mg/dL) based on the optimal cutoff value achieved in the receiver operating characteristic curve analysis. The relationships between serum TB at admission and clinical outcomes after PCI were analyzed in multivariable logistic regression models and restricted cubic spline. Results: In all patients undergoing PCI, TB>0.60 mg/dL was associated with major adverse cardiovascular events (MACE) and cardiovascular death during a 3-year follow-up. The odds ratio (95% confidence interval) was 1.60 (1.22-2.10) and 1.81 (1.22-2.70) for MACE and cardiovascular death, respectively. The association between TB and MACE was not altered by clinical presentation (p for interaction=0.949). Conclusion: In patients with ACS and SA undergoing PCI, elevated serum TB was associated with increased risk of MACE and cardiovascular death.
Introduction
Serum bilirubin is a metabolic end product of heme, which partially reflects the activity of heme oxygenase (HO). 1 In addition, bilirubin is a powerful antioxidant, which has been demonstrated to have a potential antioxidant capacity. 2, 3 The potential mechanism may be attributed to scavenging of reactive oxygen species. Bilirubin also has an antiinflammatory property based on the inhibition of endothelial adhesion molecules, such as intercellular adhesion molecule-1, vascular cell-adhesion molecule-1, and E-selectin, by tumor necrosis factor-alpha. 4 The protective effects of serum total bilirubin (TB) against cardiovascular-related disease and adverse cardiovascular events have been reported in the last decade. Serum TB has been reported to exert a protective effect on hypertension, diabetes mellitus (DM), atherosclerosis, and coronary artery disease (CAD). [5] [6] [7] [8] A meta-analysis containing a large population-based sample of 7,222 participants reported that serum TB was inversely correlated with risk of cardiovascular diseases. 9 Kim et al found that lower TB may be a predictor of adverse cardiovascular events in patients with CAD patients after primary percutaneous coronary intervention (PCI). [10] [11] [12] In patients with hypertensive and acute syndrome X, this inverse relationship between serum TB and adverse cardiovascular events remained. [13] [14] [15] Conversely, recent studies found that serum TB concentration was elevated in patients with acute myocardial infarction (MI), and several cohort studies suggested that higher serum TB was associated with adverse outcomes in patients with MI. 2, [16] [17] [18] [19] [20] [21] Based on bilirubin's anti-inflammatory and anti-oxidative properties, and different effects of serum TB on cardiovascular events in different populations, serum TB has become a heated research issue recently.
Although previous studies have evaluated the impact of the baseline serum TB on in-hospital cardiovascular outcomes after PCI, few studies have examined its influence on long-term follow-up outcomes. Furthermore, most previous studies focused on the relationship between serum TB and outcomes after PCI in patients with acute coronary syndrome (ACS), and limited evidence was available on patients with stable angina (SA). The clinical profiles and pathogenesis have been recognized to differ significantly between patients with ACS and SA. Its influence on clinical outcomes after PCI may also show differences. Our objective was to clarify the association between serum TB at admission and adverse cardiovascular events during follow up, particularly long-term clinical outcomes in patients with ACS and SA undergoing PCI.
Materials and methods Population
Study data were acquired from the Dryad Digital Repository. Our data are accessible in the Digital Repository (https://datadryad.org/resource/doi:10.5061/ dryad.13d31). All patients were collected from a single high-volume PCI center who performed successful PCI with at least one drug-eluting stent (DES) from July 2009 to August 2011. Full details of the study population and PCI procedures have been reported previously. 22, 23 Patients in this study were excluded based on the following criteria: (1) age <18 years; (2) patients with serum TB at admission >2.0 mg/dL; and (3) missing covariates or follow-up information. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University with a waiver of informed consent. Data were analyzed anonymously in this study.
Baseline data collection
All basic clinical characteristics information was collected at admission, including demographic information, cardiovascular risk factors, medication at discharge, and angiographic and procedural information. Smoking was defined as patients who smoked within the previous 10 years. Diabetes mellitus (DM) was defined as a fasting plasma glucose concentration ≥126 mg/dL or current treatment with hypoglycemic agents. Hypertension was defined as a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive drugs.
Other disease histories were self-reported. Cardiogenic shock was defined as obvious and persistent hypotension (>30 min) with systolic arterial pressure <80 mmHg with signs of hypoperfusion due to the dysfunction of the ventricles of the heart. 22 
Clinical outcomes
The primary endpoint was a long-term major adverse cardiovascular event (MACE) during a 3-year follow-up. The secondary endpoints included in-hospital and followup outcomes. In in-hospital outcomes, cardiovascular death, and nonfatal MI were observed. In long-term adverse outcomes, cardiovascular death, nonfatal MI, target vessel revascularization (TVR), any revascularization, in-stent restenosis, angina, and stroke were observed. MACE was a composite endpoint, defined as cardiovascular death, nonfatal MI, and stroke occurrence. All followup information after discharge of recruited patients was obtained through patient visits to the outpatient clinic or readmission or via a telephone interview with patients and their families. Outcome data were entered by trained research personnel, and the occurrence of adverse events was adjudicated by an independent committee not involved in the procedures.
Statistical analysis
All patients were divided into two groups: the high (>0.60 mg/dL) and low TB groups (≤0.60 mg/dL). The optimal cutoff point (0.60 mg/dL) was determined by receiver operating characteristic curve analysis. The associations of serum TB with cardiovascular events after PCI were assessed using multivariable logistic regression analysis with adjustment sets as follows: 1) unadjusted; 2) ageand sex-adjusted; and 3) multivariable: additionally adjusted for DM, hypertension, heart rate, smoking, atrial fibrillation, heart failure, history of MI, multiple diseased vessels, lesion of left main stem, restenosis lesions, ACS, triglycerides, statin, and β-blocker. To assess the shape of the association between TB and MACE, we introduced terms with common transformations of TB inclusive of linear, quadratic, logarithmic, categorical (tertiles), and binary (groups as specified above) in multivariable models and used nonparametric restricted cubic splines with four knots defined as the 5th, 35th, 65th, and 95th percentiles of the distribution of TB. The reference value for TB was 0.52 mg/dL (the median value of TB).
We also examined for interaction the effect of TB on various outcomes by clinical presentation (ACS and SA) in the multivariable model and explored the relationship between serum TB and various follow-up outcomes after PCI in two subgroups (ACS and SA) in logistic regression models after adjusting for age, sex, DM, and hypertension. A two-tailed p≤0.05 was considered statistically significant. Statistical analysis was conducted using SPSS 24.0 (IBM, Armonk, NY, USA) and SAS software 9.3 (SAS Institute Inc., Cary, NC, USA).
Results

Baseline characteristics
Of 2,533 patients who received successful PCI from July 2009 to August 2011, 31 patients were excluded based on the exclusion criteria. Finally, 2,502 patients were enrolled in this study ( Figure 1 ). The mean age was 59.9 ±11.1 years, and 68.0% of the patients were men. Clinical, laboratory, and angiographic information in the total population are listed in Table 1 had serum TB >0.60 mg/dL. The high TB group had higher initial systolic, diastolic blood pressure, heart rate, fasting blood sugar, creatinine, and uric acid level, and lower triglycerides and left ventricular ejection fraction than the low TB group. In addition, the high TB group tended to have more male patients, a higher percentage of urgent PCI, more comorbidities, including previous coronary artery bypass graft (CABG), atrial fibrillation, heart failure, and more complex lesions, including bifurcation lesions and ostial lesions compared with the low TB group.
Patients who received successful percutaneous coronary intervention (PCI) with at least one drug-eluting stents from july 2009 to august 2011 in a single hight-volume PCI center N=2533
(1) Missing covariates or follow-up anformation N=16 (2) Serum TB at admission>2.0mg/dL N=15
Stable angina patients N=410
Patients included in the study N=2502
Acute coronary syndrome patients N=2092 Figure 1 Study population selection. Abbreviation: TB, total bilirubin. .001) in the high TB group were higher than those in the low TB group. With regard to nonfatal MI, TVR, any revascularization, in-stent restenosis, angina, stroke, and all three in-hospital outcomes, no significant differences were found between the high and low TB groups. Clinical outcomes following PCI in ACS and SA patients separately are listed in Table S1 .
Covariates of serum TB
In multiple linear regression analysis, serum TB at admission had positive correlation with age (β=0.001 and 95% CI: 0.0002-0.002), male sex (β=0.078 and 95%CI: 0.051-0.104), hypertension (β=−0.024, 95%CI: −0.046 to −0.003), atrial fibrillation (β=0.124, 95%CI: 0.047-0.202), heart failure (β=0.072, 95%CI: 0.039-0.105; all p-values <0.05); see Table 3 .
Association between TB and clinical outcomes
Associations between serum TB at admission and clinical outcomes following PCI in the total population are listed in (Figure 2 ). The dose-response relationship between serum TB and MACE is given in Table 5 . Restricted cubic spline is shown in Figure 3 , and the risk of MACE increased with an increase of TB (p overall=0.025). A nonlinear doseresponse relationship between TB and MACE was not found (p nonlinear=0.208).
The association between serum TB at admission and follow-up adverse events in patients undergoing PCI was analyzed separately in patients with ACS and SA (Figure 4) . In subgroup analysis, higher TB was associated with a greater risk of MACE (OR and 95% CI, 1 
Discussion
The main finding of the present study was that serum TB level at admission was related with MACE and cardiovascular death during a 3-year follow-up with adjustment for age, sex, DM, hypertension, heart rate, smoking, atrial fibrillation, heart failure, history of MI, multiple diseased vessels, lesion of left main stem, restenosis lesions, and acute coronary syndrome. Our study result clearly showed that a high baseline serum TB level was a simple and powerful predictor of long-term MACE and cardiovascular death in patients undergoing PCI regardless of clinical presentation of CAD.
Previous literature demonstrated that increased serum TB may be protective against adverse vascular events under normal condition. [1] [2] [3] [9] [10] [11] 13, 14, [24] [25] [26] Conversely, recent reports found that initial serum TB was a prognostic marker of no-reflow and in-hospital adverse outcomes in patients with ST elevation myocardial infarction (STEMI) and MI undergoing PCI.
2,17-19,21,27 Sahin et al found that patients with STEMI with higher TB level accumulated in the high SYNTAX score group than the low SYNTAX score group. 28 The results involving TB and cardiovascular outcomes may be different between emergent and non-emergent patients, and most studies observed in-hospital outcomes in patients with ACS rather than patients with SA. Therefore, the present study might provide evidence to fully evaluate the association between serum TB and outcomes over a 3-year follow-up in patients with ACS and SA. One conceivable reason to explain the positive relationship between TB and long-term outcomes after PCI is that higher serum TB level at baseline may be a reflection of more severe disease status. It can be postulated that the elevation of bilirubin may result from inadequate arterial perfusion of liver and hepatic congestion owing to cardiac dysfunction. 21, 27 Our finding supported this hypothesis because we observed that patients with higher bilirubin concentration tended to be older and had worse co-morbidities, including atrial fibrillation and heart failure, which may cause higher possibility of long-term dismal outcomes after PCI. In addition, recent finding from Htun et al suggested that elevated bilirubin may be a surrogate marker of unstable plaques, which may cause MI, stroke, and death. 29 Another hypothesis that may explain the relationship between serum TB and unfavorable cardiovascular outcomes in patients with ACS is acute stress reaction. An inducible isoform in response to diverse cellular stress, such as oxidative stress, hypoxia, heavy metals, cytokines, and heme oxygenase 1 (HO-1), reflects the extent of inflammatory reaction to myocardial damage. In previous reports, HO-1 was found to be notably upregulated in the myocardium under infarction and pressure overload condition in animal models. 30 The study by Okuhara et al demonstrated a positive correlation between HO-1 protein and its end product bilirubin. 31 Amanvermez et al also found that oxidative end products in the first hour of patients with ACS were higher than those in the healthy population. 32 Therefore, higher serum TB concentration may also represent more serious myocardial damage in the acute period and following poor outcomes. Acute stress reaction may cause an evident correlation between TB and clinical outcomes in patients with ACS. In patients with SA, we also observed that patients with higher TB tended to have a higher risk of MACE, cardiovascular death, and nonfatal MI, although no statistical significance was observed, which may be due to the smaller sample size of patients with SA. In patients with SA, the potential positive relationship between TB and MACE may be attributed to TB as a marker of more severe disease or more severe cardiovascular dysfunction. Some limitations still need to be considered. First, only serum TB value at admission was assessed in the study. There was no information regarding the dynamic alteration of serum TB level and time points of adverse event occurrence. Confirmation of the time-dependent association between serum TB level and prognosis is impossible. Second, HO-1 and other markers related to oxidative stress were not measured. 18 Third, follow-up information obtained through a telephone interview may be an important bias in the data collection. Finally, although multivariable logistic regression analyses were performed, some potential confounding factors may not be adjusted for in our analyses because of the limited sample size.
Conclusion
We conclude that in patients with ACS and SA who underwent PCI, elevated serum TB level was associated with a greater risk of MACE and cardiovascular death. Baseline serum TB may be treated as an indicator of poor outcome after PCI regardless of whether they are patients with ACS 
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